Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02850003 · ClinicalTrials.gov registry record · Phase 1

Absorption and Systematic Pharmacokinetics of Topically Applied IDP-120 Gel

A Phase 1 study of Acne, sponsored by Bausch Health Americas.

Completed
Registry status
Phase 1
Development phase
20
Enrollment target
1
Study location

NCT02850003 is a Phase 1 study of Acne that has completed, run by Bausch Health Americas. The registered enrollment target is 20 participants, below the 142-participant average among 26 other Acne trials with a reported enrollment target (86% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02850003, a Phase 1 study of Acne, has completed, sponsored by Bausch Health Americas.

COMPLETED
Registry status
Phase 1
Development phase
20 participants
Enrollment target
1
Study location

Study Summary

Study designed to assess the safety and plasma PK of tretinoin and its metabolites from topically applied IDP-120 gel.

Conditions Studied

Interventions

  • DRUG IDP-120 Gel

Study Locations (1)

Texas

  • Valeant Site 01 - Austin

Trial Details

FieldValue
Enrollment Target 20 participants
Start Date 2016-06
Est. Completion 2016-11
Phase Phase 1

Sponsor

Bausch Health Americas

168 total trials

What the Registry Record Tells You About NCT02850003

The ClinicalTrials.gov registry entry for NCT02850003 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 142-participant average among 26 other Acne trials with a reported enrollment target (86% lower). The listed sponsor is Bausch Health Americas, which has 168 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Acne appearing as the primary indexed condition, and to 1 intervention - of which IDP-120 Gel is the first listed.

NCT02850003 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.

Frequently Asked Questions

What is clinical trial NCT02850003 about?

NCT02850003 is a clinical study titled "Absorption and Systematic Pharmacokinetics of Topically Applied IDP-120 Gel". Study designed to assess the safety and plasma PK of tretinoin and its metabolites from topically applied IDP-120 gel.

What is the current status of trial NCT02850003?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2016-06. Estimated completion is 2016-11.

What conditions does trial NCT02850003 study?

This clinical trial studies the following conditions: Acne.

What interventions are being tested in trial NCT02850003?

The interventions under investigation include: IDP-120 Gel (DRUG).

Who is sponsoring clinical trial NCT02850003?

This trial is sponsored by Bausch Health Americas, which has 168 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02850003 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Acne

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.